Sarepta Therapeutics (SRPT) News Today $46.75 -16.91 (-26.56%) Closing price 05/6/2025 04:00 PM EasternExtended Trading$38.07 -8.68 (-18.56%) As of 07:51 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period Sarepta Therapeutics: Buy Rating Affirmed Amid Revenue Challenges and Strategic AdjustmentsMay 7 at 7:20 AM | tipranks.comAlgert Global LLC Increases Stock Holdings in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)Algert Global LLC boosted its stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 8.3% during the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 74,984 shares of the biotechnology company's stock after acquiring an additional 5,778 shares duringMay 7 at 5:23 AM | marketbeat.comCaisse DE Depot ET Placement DU Quebec Purchases Shares of 19,000 Sarepta Therapeutics, Inc. (NASDAQ:SRPT)Caisse DE Depot ET Placement DU Quebec acquired a new position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund acquired 19,000 shares of the biotechnology company's sMay 7 at 4:54 AM | marketbeat.comDimensional Fund Advisors LP Acquires 30,615 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT)Dimensional Fund Advisors LP lifted its stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 10.9% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 310,810 shares of the bMay 7 at 3:48 AM | marketbeat.comSarepta Therapeutics Inc (SRPT) Q1 2025 Earnings Call Highlights: Robust Revenue Growth Amidst ...May 7 at 2:26 AM | gurufocus.comSarepta Therapeutics, Inc. (SRPT) Q1 2025 Earnings Call TranscriptMay 6 at 11:02 PM | seekingalpha.comStocks to Watch: Super Micro Computer, Electronic Arts, WW International, Sarepta TherapeuticsMay 6 at 8:50 PM | marketwatch.comSarepta Therapeutics Shares Fall on Full-Year Outlook Cut, Swing to 1Q LossMay 6 at 8:50 PM | marketwatch.comSarepta Therapeutics (NASDAQ:SRPT) Surprises With Q1 Sales But Stock Drops 22.8%May 6 at 8:50 PM | msn.comSarepta Therapeutics (SRPT) Slashes 2025 Revenue Forecast, Shares PlungeMay 6 at 7:19 PM | gurufocus.comSarepta Therapeutics Stock Plummets After Q1 Results: Here's WhyMay 6 at 6:13 PM | benzinga.comSarepta Therapeutics (SRPT) Reports Mixed Q1 Earnings ResultsMay 6 at 5:47 PM | gurufocus.comSarepta Therapeutics Announces First Quarter 2025 Financial Results and Recent Corporate ...May 6 at 5:47 PM | gurufocus.comSarepta Therapeutics Announces First Quarter 2025 Financial Results and Recent Corporate ...May 6 at 4:56 PM | gurufocus.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPTMay 6 at 4:13 PM | prnewswire.comSarepta Therapeutics Announces First Quarter 2025 Financial Results and Recent Corporate DevelopmentsMay 6 at 4:05 PM | businesswire.comBellevue Group AG Has $20.83 Million Stock Position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)Bellevue Group AG lessened its position in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 50.2% in the fourth quarter, according to its most recent filing with the SEC. The firm owned 171,317 shares of the biotechnology company's stock after selling 173,031 shares during the quMay 6 at 6:33 AM | marketbeat.comNorthern Trust Corp Has $97.70 Million Position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)Northern Trust Corp raised its holdings in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 22.6% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 803,511 shares of the biotechnology compMay 6 at 4:39 AM | marketbeat.comEarnings To Watch: Sarepta Therapeutics (SRPT) Reports Q1 Results TomorrowMay 5 at 3:59 PM | msn.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Sarepta Therapeutics, Inc. - SRPTMay 5 at 1:53 PM | globenewswire.comSRPT Investors Have Opportunity to Join Sarepta Therapeutics, Inc. Fraud Investigation with the Schall Law FirmMay 5 at 9:00 AM | prnewswire.comAlkeon Capital Management LLC Acquires 220,000 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT)Alkeon Capital Management LLC lifted its holdings in Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 34.7% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 853,845 sharesMay 5 at 7:44 AM | marketbeat.comThe Manufacturers Life Insurance Company Increases Stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)The Manufacturers Life Insurance Company grew its stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 159.0% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 193,652 shares of theMay 5 at 5:01 AM | marketbeat.com683 Capital Management LLC Buys 14,778 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT)683 Capital Management LLC boosted its position in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 16.9% during the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 102,000 shares of the biotechnology company's stockMay 4 at 7:14 AM | marketbeat.comSchonfeld Strategic Advisors LLC Decreases Stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)Schonfeld Strategic Advisors LLC decreased its stake in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 19.5% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 49,410 shares of the biMay 4 at 5:06 AM | marketbeat.comPrice T Rowe Associates Inc. MD Acquires 5,130 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT)Price T Rowe Associates Inc. MD increased its holdings in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 2.2% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 241,663 sharesMay 3, 2025 | marketbeat.comSarepta Therapeutics, Inc. (NASDAQ:SRPT) Shares Sold by PDT Partners LLCPDT Partners LLC lowered its stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 59.6% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 15,748 shares of the biotechnology company's stock aftMay 2, 2025 | marketbeat.comSarepta Therapeutics (SRPT) Projected to Post Quarterly Earnings on TuesdaySarepta Therapeutics (NASDAQ:SRPT) will be releasing its Q1 2025 earnings after the market closes on Tuesday, May 6. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2025-5-6-sarepta-therapeutics-inc-stock/)May 1, 2025 | marketbeat.comSoros Fund Management LLC Raises Position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)Soros Fund Management LLC increased its stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 11.8% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 230,893 shares of the biotechnology companMay 1, 2025 | marketbeat.comEmerald Mutual Fund Advisers Trust Has $2.32 Million Holdings in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)Emerald Mutual Fund Advisers Trust increased its holdings in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 1,776.2% in the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 19,100 shares of the biotechnology compMay 1, 2025 | marketbeat.com1 of Wall Street’s Favorite Stock on Our Buy List and 2 to Approach with CautionMay 1, 2025 | finance.yahoo.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Sarepta Therapeutics, Inc. – SRPTApril 29, 2025 | globenewswire.comSRPT Investors Have Opportunity to Join Sarepta Therapeutics, Inc. Fraud Investigation with the Schall Law FirmApril 29, 2025 | prnewswire.comAdage Capital Partners GP L.L.C. Sells 100,000 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT)Adage Capital Partners GP L.L.C. decreased its stake in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 36.4% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 175,000 shares of the biotechnology compaApril 29, 2025 | marketbeat.comSarepta Therapeutics, Inc. (NASDAQ:SRPT) Shares Bought by Pinebridge Investments L.P.Pinebridge Investments L.P. increased its position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 42.7% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 25,143 shares of the biotechnology coApril 29, 2025 | marketbeat.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPTApril 28, 2025 | prnewswire.com4,112 Shares in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Acquired by Syon Capital LLCSyon Capital LLC purchased a new stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor purchased 4,112 shares of the biotechnology company's stock, valApril 27, 2025 | marketbeat.comFirst Trust Advisors LP Trims Stock Position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)First Trust Advisors LP cut its position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 32.9% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 311,785 shares of the biotechnology company's stockApril 27, 2025 | marketbeat.comT. Rowe Price Investment Management Inc. Raises Holdings in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)T. Rowe Price Investment Management Inc. increased its holdings in Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 0.5% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 1,956,583 shares of the bApril 26, 2025 | marketbeat.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPTApril 25, 2025 | globenewswire.comTower Research Capital LLC TRC Grows Position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)Tower Research Capital LLC TRC raised its stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 58.7% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 14,522 shares of the biotechnology company's stock after acquiring an addApril 25, 2025 | marketbeat.comMetLife Investment Management LLC Purchases 4,422 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT)MetLife Investment Management LLC boosted its position in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 8.3% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 57,749 shares of the biotechnology company's stock aApril 25, 2025 | marketbeat.comPiper Sandler Reaffirms Their Buy Rating on Sarepta Therapeutics (SRPT)April 24, 2025 | markets.businessinsider.comSRPT Investors Have Opportunity to Join Sarepta Therapeutics, Inc. Fraud Investigation with the Schall Law FirmApril 24, 2025 | prnewswire.comSarepta Therapeutics (SRPT): Among Billionaire George Soros’ Small-Cap Stocks with Huge Upside PotentialApril 24, 2025 | finance.yahoo.comPiper Sandler Has Lowered Expectations for Sarepta Therapeutics (NASDAQ:SRPT) Stock PricePiper Sandler lowered their price target on Sarepta Therapeutics from $182.00 to $110.00 and set an "overweight" rating on the stock in a report on Monday.April 23, 2025 | marketbeat.comCapital International Inc. CA Raises Stock Holdings in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)Capital International Inc. CA grew its holdings in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 193.2% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 22,493 shares of the biotechnologyApril 23, 2025 | marketbeat.comEnvestnet Asset Management Inc. Boosts Stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)Envestnet Asset Management Inc. grew its position in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 11.9% during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 45,614 shares of thApril 23, 2025 | marketbeat.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPTApril 22, 2025 | prnewswire.comSarepta Therapeutics to Announce First Quarter 2025 Financial ResultsApril 22, 2025 | businesswire.com Get Sarepta Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SRPT and its competitors with MarketBeat's FREE daily newsletter. Email Address SRPT Media Mentions By Week SRPT Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. SRPT News Sentiment▼1.110.69▲Average Medical News Sentiment SRPT News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. SRPT Articles This Week▼2813▲SRPT Articles Average Week Get Sarepta Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SRPT and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies BioNTech News Today Summit Therapeutics News Today Teva Pharmaceutical Industries News Today Intra-Cellular Therapies News Today Genmab A/S News Today Dr. Reddy's Laboratories News Today Moderna News Today Ascendis Pharma A/S News Today Viatris News Today Qiagen News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:SRPT) was last updated on 5/7/2025 by MarketBeat.com Staff From Our PartnersElon’s Terrifying Warning Forces Trump To Take ActionElon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...American Hartford Gold | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredTrump’s Bitcoin Reserve is No Accident…Bryce Paul believes this is the #1 coin to buy right now The catalyst behind this surge is a massive new b...Crypto 101 Media | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredMusk's warning signal: Prepare before the cascade beginsWhen Elon Musk triggered his AI layoff plan, most analysts missed what it really meant. Louis Navellier didn’t...InvestorPlace | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sarepta Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sarepta Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy SRPT Stock Free SRPT Stock Alerts